Clinical trial
Treatment of Children and Adolescents With Growth Failure Associated With…
NCT00330668 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00330668 |
|---|---|
| Title | Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency |
| Official title | Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Disorders |
| Intervention type | Drug |
| Interventions | rh IGF-1 (mecasermin) |
| Enrollment | 114 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | May 29, 2006 |
| Last update posted | Aug 14, 2020 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: